Latest Conference Articles

September 21st 2021, 10:05pm

ESMO Congress: Lung Cancer

The median real-world progression-free survival with durvalumab was higher compared with the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

September 21st 2021, 9:40pm

ESMO Congress

Fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels in patients with HER2-positive, metastatic colorectal cancer.

September 21st 2021, 9:37pm

International Workshop on CLL

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

September 21st 2021, 9:30pm

International Workshop on CLL

Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

September 21st 2021, 7:27pm

ESMO Congress: GI Cancers

Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

September 21st 2021, 5:11pm

ESMO Congress: Lung Cancer

The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.

September 21st 2021, 3:50pm

ESMO Congress: Breast Cancer

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

September 21st 2021, 3:29pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.

September 21st 2021, 2:24pm

International Workshop on CLL

During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.

September 21st 2021, 1:14pm

ESMO Congress: Lung Cancer

Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

September 21st 2021, 1:14pm

ESMO Congress

Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.

September 20th 2021, 10:10pm

International Workshop on CLL

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.

September 20th 2021, 9:42pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

September 20th 2021, 9:37pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

September 20th 2021, 9:25pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer. 

September 20th 2021, 9:23pm

International Workshop on CLL

William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

September 20th 2021, 9:20pm

International Workshop on CLL

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

September 20th 2021, 8:13pm

International Workshop on CLL

A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.

September 20th 2021, 7:34pm

ESMO Congress

Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.

September 20th 2021, 7:24pm

International Workshop on CLL

Zanubrutinib monotherapy showed a deepening of response in patients with relapsed/refractory chronic lymphocytic leukemia.